Press Releases

Supreme Court Exempts Saridon from the List of Banned FDCs

Piramal Imaging and ASAN Medical Center announce Research and Development Collaboration Agreement

Piramal Imaging to Present New Research in PET Imaging at CTAD Annual Meeting

Piramal Pharma Solutions wins at prestigious CPhI Pharma Awards

Piramal Imaging Announces Strategic Partnership with PET Pharm Biotech for Exclusive Commercialization of Neuraceq™ in Taiwan

Piramal healthcare invests £2.0 mn in scotland

Piramal Imaging Presents New Data on Florbetaben in Detecting Beta-amyloid Plaques in Patients with Suspected Alzheimer’s Disease

Piramal Enterprises renames its ovulation test kit brand as “i-know”

Piramal Imaging SA and Ci-Co Healthcare Announce Commercial Approval of Neuraceq™ in Korea

Decision Resources Group Sets Course in Helping Leading Healthcare Companies Understand the Convergence of Healthcare Markets

Piramal Imaging is Proud to Support Major New Research Study Assessing the Value of PET Scans in Alzheimer’s Disease and Dementia Diagnosis

Piramal Enterprises considers potential acquisition of Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc.

Piramal Enterprises’ Pharma Solution division receives four CMO Leadership Awards 2015

Piramal Enterprises’ Consumer Product division ropes in Juhi Chawla as brand ambassador for their brand ‘Jungle Magic’

Piramal Imaging Taps M2i to Manufacture and Distribute NeuraCeq , in Ireland

Piramal Enterprises ropes in Sharman Joshi as brand ambassador for their latest OTC product offering -‘QuikKool’

Piramal Sarvajal successfully completes a year in Jaipur through their ‘Jaipur Schools Program’

First US Commercial Neuraceq , Scan for Beta-Amyloid Plaque Imaging Performed at WVU Healthcare

First Site in Europe Begins to Offer Commercial Scans Using Piramal Imaging’s NeuraCeq , for Beta-Amyloid Plaque Imaging

Piramal’s NCE Research shared Preclinical efficacy data for Two Promising Molecules at the American Diabetes Association’s 74th Scientific Sessions

Research on Piramal Imaging’s NeuraceqTM (florbetaben F18 injection) takes Center Stage at SNMMI

Piramal imaging research key topic at society of nuclear medicine and molecular imaging annual meeting

AC Immune and Piramal Imaging announce out-licensing agreement for the development of Tau protein diagnostics in Alzheimer’s disease

NeuraceqTM (florbetaben F18 injection) Data: an Emerging Science Topic at the American Academy of Neurology Annual Meeting in Philadelphia

Piramal Enterprises’ Pharma Solution Division receives two coveted CMO Leadership Awards (2013) for “Quality ” and “Reliability “

Piramal Imaging Announces EU Approval of NeuraCeqTM (florbetaben 18F)* for PET Imaging of Beta-Amyloid Neuritic Plaque Density in the Brain

CHMP Recommends EU Approval of Piramal Imaging’s NeuraCeqTM (Florbetaben 18F)* for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain

Piramal Imaging Enters into a Strategic Partnership and Exclusive Licensing Agreement with Ci-Co Healthcare for Commercialization of Florbetaben F18

Piramal Enterprises acquires the brand CALADRYL ? in India

Piramal | Healthcare to invest $ 11 million in hormonal healthcare production at its Morpeth, UK, facility

Piramal Imaging provides comments in response to the centers for Medicare and Medicaid Services’ (Cms’) proposed coverage decision for Beta-Amyloid Positron Emission Tomography (Pet)

Piramal Imaging Welcomes Ana M. Catafau, M.D., Ph.D., as VP, Clinical Research and Development, Neurosciences

Piramal Enterprises’ expands its Jungle Magic portfolio with the launch of Banditz

Piramal Enterprise celebrates the enduring beauty of “Audrey Hepburn ” with the launch of, “Lacto Calamine RENEU “, an all new anti-ageing cream

Piramal Imaging announces the acceptance for review of [18F] florbetaben by the FDA and EMA for the visual detection of beta-amyloid in Alzheimer’s disease

Piramal Healthcare announces settlement of patent litigation with Baxter Halthcare related to generic version of SUPRANE (Desflurane)

Piramal Healthcare Limited to acquire the Anesthetic products business of Bharat Serums And Vaccines Limited

Revenues for FY2009 up by 14.4% to Rs. 32.8 billion

Piramal Healthcare Limited Acquires U.S. Inhalation Anesthetic Gas Distribution Business of RxElite, Inc.

Piramal Healthcare Limited Completes Acquisition of Minrad International, Inc.